Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426014626?dgcid=rss_sd_all
Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426014626?dgcid=rss_sd_all
“Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study.” Annals of Oncology.
@article{article35939,
title = {Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426014626?dgcid=rss_sd_all}
}